Finance
The Centre has approved Biological E’s Corbevax as a precaution dose after six months from the date of administration of the second dose of either Covaxin or Covishield vaccines for the population over the age of 18, said Union Health Secretary Rajesh Bhushan,
Corbevax, India’s first indigenously developed RBD protein subunit vaccine, is currently being used in the immunization program to inoculate children aged 12 to 14 years.
In its July 20 meeting, the COVID-19 Working Group (CWG) reviewed data from a double-blind randomised phase-3 clinical study that assessed the immunogenicity and safety of a booster dose of Corbevax vaccine when administered to COVID-19-negative adult volunteers aged 18-80 years who had previously received two doses of either Covishield or Covaxin.
From January 10, India began administering vaccine precaution doses to healthcare and frontline workers, as well as those aged 60 and older with comorbidities.
From March 16, the country began immunizing children aged 12 to 14, and it also removed the comorbidity clause, making all people over the age of 60 eligible for the precaution dose of Covid vaccine.
On April 10, India began administering vaccine precaution doses to all adults over the age of 18.
Source:HT
